We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go: Expired investment: £451,506
The Company has been formed for the sole purpose of seeking finance for producing and exploiting the feature film, "E=Motion". The Company intends to raise up to one hundred and fifty thousand pounds Sterling (£150,000).
days to go: Expired investment: £14,975
The Company is seeking finance for producing the feature film, "E=Motion", a sci-fi movie about a road trip to the end of the universe. E=Motion offers mass appeal as a dramatic sci-fi thriller.
days to go: Expired investment: £13,175
Regenerative Medical Group provides a remedy for Wound Healing and Erectile Dysfunction (ED) by using non-invasive technology. It partners with clinics to render the service such as reception, treatment rooms and nurses. In addition to the Erectile Dysfunction (ED) market, it has identified wound healing as a new market. Currently, it is working with an experienced NHS/NICE validation team to show its value as a treatment modality. RMG reached revenues of £400k, -56k EBITDA in the financial year 2017, and is operational in 5 clinics.
days to go: Expired investment: £67,740
Olberon is a UK based medical device innovations company seeking to raise funds for manufacturing and the sale of Vacuderm which is a device designed to assist with childrens cannulation procedure. Olberon Ltd has already got a strong portfolio of patented medical innovations and two medical devices which are market ready.
days to go: Expired investment: £5,634
Reducing the cost of orthopaedic equipment by using compression screws and titanium maxiangle locking plates. DC Surgical Supplies have acquired an exclusive license with Palmer & Baker with the aim of helping the NHS cut the cost of purchasing regular-use equipment by as much as 35%. Their product is CE Certified and has been featured in The Telegraph.
days to go: Expired investment: £99,000
Seadog TV and Film Productions create and film television programmes.  Since the launch of the Seadog they have taken part in several commercial projects and have received a nomination from the royal television society for excellence and factual film making.   They are looking to launch Leaderbox which uses the power of film to engage young people with the Leaderbox system.  The investment will fund a commercial manager and grow their development team.
days to go: Expired investment: £509,820
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
FortuneHunterTV is the UK’s only TV Series providing specialist advice and bespoke content for small business owners. 100% for entrepreneurs by entrepreneurs.We have a defined targeted audience, delivering our content to them via their phones, tablets, computers and televisions.As Lyndon Wood says “FortuneHunter TV is full of nuggets of information, delivered to you by people who have actually faced the same problem, and overcome it successfully. Its like having an entire group of mentors on your phone or in your living room”There has never been a better time to invest in a business that encourages and supports budding entrepreneurs in the UK
days to go: Expired investment: £9,240
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph